Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

"Today we're proud to announce that we're joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes." The company says it will ...

The new trial investigated the role of the Pro version of the mySugr app, a digital diabetes logbook which Roche acquired along with its developer in 2017 and – in a defining moment for digital ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Mar. 11, 2025 — New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions ...

Public Service Commissioner Sir Brian Roche fears the sheer number of entities, departments and agencies – some of which are small – creates inefficiencies and duplication.